Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
revised:
23
11
2021
received:
31
08
2021
accepted:
07
12
2021
pubmed:
10
1
2022
medline:
17
3
2022
entrez:
9
1
2022
Statut:
ppublish
Résumé
The long-term evolution of children with segmental facial infantile haemangioma (SFIH) treated with propranolol remains unstudied. The objective of this study was to evaluate the neurodevelopmental features of children with SFIH treated with propranolol at 6 years of age. This retrospective case series study was conducted from January 2008 to June 2020 using data from medical files, patient examinations and appointments spanning 6 years. To be included, patients should present SFIH and have previously received propranolol. A complete physical examination, magnetic resonance imaging (MRI) of the head, echocardiography and ophthalmologic examination should have been performed. Neurodevelopmental features were divided into cognition, audition, vision, orality, motor skills and the occurrence of new symptoms. Thirty children with SFIH were included. Of these, 11 presented criteria of PHACES. Evaluation of neurodevelopmental features of the children at 6 years of age showed learning difficulties in one case but grade skipping in three cases. There were six cases of unilateral hearing loss that had not been diagnosed at birth, two of oral difficulties and one of minor hypotonia. Early headache was primarily reported as the main new outcome. All children were treated with propranolol, with three following oral steroid therapy. No severe adverse effects were reported. The median length of treatment with propranolol was 16 months, and the median age at treatment cessation was 21 months. Analysis based on segment implication showed the median length of treatment to vary from 12 months (if S3 was spared) to 25 months (if at least S3 was involved). Vascular laser therapy was used in 16 patients (53.3%) and surgery in four. In this case series, children with SFIH, including patients with PHACES criteria, presented a good tolerance of propranolol, as well as encouraged neurodevelopmental data. Segmental implication appears to have a significant impact on treatment duration and associated complications.
Sections du résumé
BACKGROUND
BACKGROUND
The long-term evolution of children with segmental facial infantile haemangioma (SFIH) treated with propranolol remains unstudied.
OBJECTIVES
OBJECTIVE
The objective of this study was to evaluate the neurodevelopmental features of children with SFIH treated with propranolol at 6 years of age.
METHODS
METHODS
This retrospective case series study was conducted from January 2008 to June 2020 using data from medical files, patient examinations and appointments spanning 6 years. To be included, patients should present SFIH and have previously received propranolol. A complete physical examination, magnetic resonance imaging (MRI) of the head, echocardiography and ophthalmologic examination should have been performed. Neurodevelopmental features were divided into cognition, audition, vision, orality, motor skills and the occurrence of new symptoms.
RESULTS
RESULTS
Thirty children with SFIH were included. Of these, 11 presented criteria of PHACES. Evaluation of neurodevelopmental features of the children at 6 years of age showed learning difficulties in one case but grade skipping in three cases. There were six cases of unilateral hearing loss that had not been diagnosed at birth, two of oral difficulties and one of minor hypotonia. Early headache was primarily reported as the main new outcome. All children were treated with propranolol, with three following oral steroid therapy. No severe adverse effects were reported. The median length of treatment with propranolol was 16 months, and the median age at treatment cessation was 21 months. Analysis based on segment implication showed the median length of treatment to vary from 12 months (if S3 was spared) to 25 months (if at least S3 was involved). Vascular laser therapy was used in 16 patients (53.3%) and surgery in four.
CONCLUSION
CONCLUSIONS
In this case series, children with SFIH, including patients with PHACES criteria, presented a good tolerance of propranolol, as well as encouraged neurodevelopmental data. Segmental implication appears to have a significant impact on treatment duration and associated complications.
Substances chimiques
Adrenergic beta-Antagonists
0
Propranolol
9Y8NXQ24VQ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
610-614Informations de copyright
© 2022 European Academy of Dermatology and Venereology.
Références
Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet 2017; 390: 85-94.
Haggstrom AN. Patterns of infantile hemangiomas: new clues to hemangioma pathogenesis and embryonic facial development. Pediatrics 2006; 117: 698-703.
Forde KM, Glover MT, Chong WK, Kinsler VA. Segmental hemangioma of the head and neck: high prevalence of PHACE syndrome. J Am Acad Dermatol 2017; 76: 356-358.
Haggstrom AN, Garzon MC, Baselga E et al. Risk for PHACE syndrome in infants with large facial hemangiomas. Pediatrics 2010; 126: e418-e426.
Garzon MC, Epstein LG, Heyer GL et al. PHACE syndrome: consensus-derived diagnosis and care recommendations. J Pediatr 2016; 178: 24-33.e2.
Metry DW, Haggstrom AN, Drolet BA et al. A prospective study of PHACE syndrome in infantile hemangiomas: demographic features, clinical findings, and complications. Am J Med Genet 2006; 140A: 975-986.
Olsen GM, Hansen LM, Stefanko NS et al. Evaluating the safety of oral propranolol therapy in patients with PHACE syndrome. JAMA Dermatol 2020; 156: 186.
Disse SC, Zemlin M, Mueller C, Meyer S. PHACE syndrome-before and after propranolol therapy. J Pediatr 2018; 193: 275.
Metry D, Frieden IJ, Hess C et al. Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants. Pediatr Dermatol 2013; 30: 71-89.
Hess CP, Fullerton HJ, Metry DW et al. Cervical and intracranial arterial anomalies in 70 patients with PHACE syndrome. Am J Neuroradiol 2010; 31: 1980-1986.
Jernigan S, Storey A, Hammer C et al. Moyamoya syndrome and PHACE syndrome: clinical and radiographic characterization of the intracranial arteriopathy and response to surgical revascularization. J Neurosurg Pediatr 2019; 23: 493-497.
Habib M, Manilha R, Khan N. Management of PHACES syndrome: Risk of stroke and its prevention from a neurosurgical perspective. Eur J Paediatr Neurol 2020; 26: 39-45.
Metry DW, Dowd CF, Barkovich AJ, Frieden IJ. The many faces of PHACE syndrome. J Pediatr 2001; 139: 117-123.
Morton PD, Ishibashi N, Jonas RA. Neurodevelopmental abnormalities and congenital heart disease: insights into altered brain maturation. Circ Res 2017; 120: 960-977.
Nattel SN, Adrianzen L, Kessler EC et al. Congenital heart disease and neurodevelopment: clinical manifestations, genetics, mechanisms, and implications. Can J Cardiol 2017; 33: 1543-1555.
Gaynor JW, Stopp C, Wypij D et al. Neurodevelopmental outcomes after cardiac surgery in infancy. Pediatrics 2015; 135: 816-825.
Brosig CL, Siegel DH, Haggstrom AN, Frieden IJ, Drolet BA. Neurodevelopmental outcomes in children with PHACE syndrome. Pediatr Dermatol 2016; 33: 415-423.
Tangtiphaiboontana J, Hess CP, Bayer M et al. Neurodevelopmental abnormalities in children with PHACE syndrome. J Child Neurol 2013; 28: 608-614.
Martin KL, Arvedson JC, Bayer ML, Drolet BA, Chun R, Siegel DH. Risk of dysphagia and speech and language delay in PHACE syndrome. Pediatr Dermatol 2015; 32: 64-69.
Kohr LM, Dargan M, Hague A et al. The incidence of dysphagia in pediatric patients after open heart procedures with transesophageal echocardiography. Ann Thorac Surg 2003; 76: 1450-1456.
Duffy KJ, Runge-Samuelson C, Bayer ML et al. Association of hearing loss with PHACE syndrome. Arch Dermatol 2010; 146: 1391.
Mamlouk MD, Zimmerman B, Mathes EF, Rosbe KW. Hearing loss in PHACE syndrome: clinical and radiologic findings. Childs Nerv Syst 2018; 34: 1717-1724.
Yu J, Siegel DH, Drolet BA et al. Prevalence and clinical characteristics of headaches in PHACE syndrome. J Child Neurol 2016; 31: 468-473.
Stefanko NS, Cossio M, Powell J et al. Natural history of PHACE syndrome: a survey of adults with PHACE. Pediatr Dermatol 2019; 36: 618-622.
Léauté-Labrèze C, de la Roque ED, Hubiche T, Boralevi F, Thambo J-B, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651.
Leaute-Labreze C, Boccara O, Degrugillier-Chopinet C et al. Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Pediatrics 2016; 138: e20160353.
Siegel DH, Tefft KA, Kelly T et al. Stroke in children with posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities (PHACE) syndrome: a systematic review of the literature. Stroke 2012; 43: 1672-1674.
Püttgen KB, Hansen LM, Lauren C et al. Limited utility of repeated vital sign monitoring during initiation of oral propranolol for complicated infantile hemangioma. J Am Acad Dermatol 2020; 85: 345-352.
George ME, Sharma V, Jacobson J, Simon S, Nopper AJ. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. Arch Dermatol 2004; 140: 963-969. https://doi.org/10.1001/archderm.140.8.963
Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011; 128: e259-e266.
Baselga E, Dembowska-Baginska B, Przewratil P et al. Efficacy of propranolol between 6 and 12 months of age in high-risk infantile hemangioma. Pediatrics 2018; 142: e20173866.